Clinical Trial
2023-506290-35-00 Recruiting, Active
A Study to Investigate the Safety, Tolerability, and Exposure of Single Doses of the study medicine STK-002, in Patients with Autosomal Dominant Optic Atrophy (ADOA)
A Study to Investigate the Safety, Tolerability, and Exposure of Single Doses of the study medicine STK-002, in Patients with Autosomal Dominant Optic Atrophy (ADOA)
Disease
Disease type
ADOA
Patient type
Adult
Children
Inclusion / Exclusion
Funding
Industry
Members involved
Main investigators
Pr Michael LARSEN
Representative
Denmark
Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
Univ.-Prof. Dr. k.m.n. PhD Lyubomyr Lytvynchuk
Representative
Germany
Anterior Segment Rare Eye Diseases (WG4), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Pr Katarina Stingl
Representative
Germany
Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
ERN EYE member investigating site
HCP : Principal investigators
Rigshospitalet, Copenhagen, Denmark
Adress
Inge Lehmanns Vej 7 Entrance 2, 6. floor Section 2061
2100 Copenhagen
Denmark
Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany
Adress
Klinik und Poliklinik für Augenheilkunde Friedrichstr. 18
35392 Gießen
Germany
Medical University of Vienna, Dept of Ophthalmology, Vienna, Austria
Adress
Spitalgasse 23
1090 Vienna
Austria